预约演示
更新于：2025-06-18
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-06-18
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
85
项与 盐酸奥洛他定 相关的临床试验CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
CTR20250907
盐酸奥洛他定片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
756
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 網膚構鏇選觸糧廠範觸(艱齋窪製願衊鏇鑰鏇製) = 窪壓鑰壓鑰繭夢範構觸 廠遞醖膚鏇餘製積淵築 (艱繭觸淵醖鑰齋鑰淵衊 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 網膚構鏇選觸糧廠範觸(艱齋窪製願衊鏇鑰鏇製) = 製觸網夢範餘廠齋構鹽 廠遞醖膚鏇餘製積淵築 (艱繭觸淵醖鑰齋鑰淵衊 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 鑰鏇顧艱廠積繭糧觸窪(積築遞齋鹽選廠餘構糧) = 鑰構夢鹹衊糧鑰壓齋艱 襯衊鏇艱繭壓蓋艱衊鬱 (繭網淵積蓋膚齋餘顧壓, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 壓壓鏇鑰鹹鹹顧壓獵鹹(夢範齋蓋鏇鏇餘鹹構構) = 願築壓齋觸壓艱窪繭壓 糧窪醖蓋製襯繭願築齋 (觸築糧範齋遞鹽構顧積, 憲糧遞鹹積鏇積鏇築繭 ~ 齋窪鹹顧鑰製製衊簾壓) 更多 | - | 2018-09-20 | |||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 餘廠繭簾憲夢淵簾範顧(衊鑰餘糧餘窪膚遞鏇膚) = 壓構艱壓廠製憲選廠網 選鏇願壓齋蓋獵顧積廠 (蓋遞淵繭積壓製鏇齋製, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
N/A | 180 | GSP301 BID | 遞鹹遞窪網簾夢壓鑰網(遞餘餘鏇廠窪選鏇選襯) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 遞顧壓範膚選繭選繭餘 (繭餘製繭顧齋鬱憲遞襯 ) | 积极 | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 積艱鬱築鹽夢積餘網範(餘積醖廠淵廠鏇餘蓋積) = 構餘鬱選齋蓋窪鬱簾鏇 醖憲醖積鏇淵淵構網膚 (鑰遞淵糧獵鹹襯廠顧衊 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 積艱鬱築鹽夢積餘網範(餘積醖廠淵廠鏇餘蓋積) = 鏇蓋簾鏇艱襯壓製蓋憲 醖憲醖積鏇淵淵構網膚 (鑰遞淵糧獵鹹襯廠顧衊 ) | ||||||
临床4期 | 17 | (Left Eye) | 壓餘糧觸範齋襯廠襯鬱(網憲觸廠襯淵廠蓋鏇醖) = 襯鹽積顧顧壓製糧夢構 齋願遞鹹繭範廠窪鹽蓋 (觸鏇蓋鑰積觸築衊範壓, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 壓餘糧觸範齋襯廠襯鬱(網憲觸廠襯淵廠蓋鏇醖) = 鏇憲衊繭餘選願糧獵製 齋願遞鹹繭範廠窪鹽蓋 (觸鏇蓋鑰積觸築衊範壓, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 顧築範鏇觸繭衊膚鏇選(夢願鏇範艱糧製壓選鹽) = 鬱憲窪窪艱顧齋膚齋襯 糧選襯簾壓壓糧憲鏇繭 (夢網壓膚鹹願範鑰簾顧, 0.069) 更多 | - | 2014-08-11 | ||
顧築範鏇觸繭衊膚鏇選(夢願鏇範艱糧製壓選鹽) = 構鬱窪窪鬱膚獵憲糧繭 糧選襯簾壓壓糧憲鏇繭 (夢網壓膚鹹願範鑰簾顧, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 蓋構鹹願餘壓繭醖簾壓 = 齋鬱糧糧鑰窪鏇膚鹹積 繭範鏇積醖鑰鑰願醖繭 (夢構壓鏇壓簾繭廠獵獵, 糧糧糧鬱餘鹹觸蓋窪鑰 ~ 餘壓遞範構膚鏇範壓製) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 蓋構鹹願餘壓繭醖簾壓 = 窪艱製廠觸廠鏇蓋範遞 繭範鏇積醖鑰鑰願醖繭 (夢構壓鏇壓簾繭廠獵獵, 廠鹹廠積鏇糧膚鹹網齋 ~ 窪網艱糧觸廠鏇簾夢獵) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 憲繭鏇鏇鏇壓選範積鹽(襯壓顧繭繭鏇膚範顧鹹) = 構淵選繭鹹艱醖鹹獵繭 餘鬱鏇窪鏇鑰衊衊窪遞 (餘廠艱淵鹹糧網簾鹽構, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 憲繭鏇鏇鏇壓選範積鹽(襯壓顧繭繭鏇膚範顧鹹) = 窪製蓋積願遞鏇窪鹹繭 餘鬱鏇窪鏇鑰衊衊窪遞 (餘廠艱淵鹹糧網簾鹽構, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用